Answers are grounded in this paper and cite their sources.
Review highlights recent nano-therapeutics advances for immune cell engineering, suggesting implications for accessibility and safety.
Front Cover In article number e01973, Haochen Yao, Shixian Lv, Yu Tao, Mingqiang Li, and co-workers review recent advances in nano-therapeutics for in vivo immune cell engineering, an approach offering significant advantages over ex vivo methods, including lower cost, reduced manufacturing time, and simplified procedures. They summarize the latest progress and therapeutic applications of these strategies across various diseases, discuss critical challenges such as targeting specificity and safety, and explore potential solutions to accelerate clinical translation and broaden patient access. This review provides a timely roadmap for advancing in vivo engineering towards broader clinical translation.
No takes yet. Share an insight, caveat, or question.
Geng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: